223镭在常规临床中的有效性和安全性

IF 0.1 Q4 ONCOLOGY

Onkourologiya Pub Date : 2021-02-10 DOI:10.17650/1726-9776-2020-16-4-129-135

V. Matveev, A. Markova

{"title":"223镭在常规临床中的有效性和安全性","authors":"V. Matveev, A. Markova","doi":"10.17650/1726-9776-2020-16-4-129-135","DOIUrl":null,"url":null,"abstract":"Several treatment options are currently available for patients with metastatic castration-resistant prostate cancer in routine clinical practice. However, clear standards of sequential use of registered drugs have not yet been developed. Affecting bone metastases, radium-223 is one of therapeutic options for patients with castration-resistant prostate cancer and bone metastases, which was included in foreign and Russian guidelines for prostate cancer management. This article analyzes the results of treatment with radium-223 in patients with metastatic castration-resistant prostate cancer in foreign non-interventional clinical trials conducted in routine clinical practice. These trials confirmed high efficacy and safety of radium-223 demonstrated earlier in the ALSYMPCA trial. Some protocols ensured better overall survival rates and lower incidence of symptomatic skeletal events and adverse events than those in the registration study.","PeriodicalId":42924,"journal":{"name":"Onkourologiya","volume":"1 1","pages":""},"PeriodicalIF":0.1000,"publicationDate":"2021-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Efficacy and safety of radium-223 in routine clinical practice\",\"authors\":\"V. Matveev, A. Markova\",\"doi\":\"10.17650/1726-9776-2020-16-4-129-135\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Several treatment options are currently available for patients with metastatic castration-resistant prostate cancer in routine clinical practice. However, clear standards of sequential use of registered drugs have not yet been developed. Affecting bone metastases, radium-223 is one of therapeutic options for patients with castration-resistant prostate cancer and bone metastases, which was included in foreign and Russian guidelines for prostate cancer management. This article analyzes the results of treatment with radium-223 in patients with metastatic castration-resistant prostate cancer in foreign non-interventional clinical trials conducted in routine clinical practice. These trials confirmed high efficacy and safety of radium-223 demonstrated earlier in the ALSYMPCA trial. Some protocols ensured better overall survival rates and lower incidence of symptomatic skeletal events and adverse events than those in the registration study.\",\"PeriodicalId\":42924,\"journal\":{\"name\":\"Onkourologiya\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.1000,\"publicationDate\":\"2021-02-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Onkourologiya\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.17650/1726-9776-2020-16-4-129-135\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Onkourologiya","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17650/1726-9776-2020-16-4-129-135","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Efficacy and safety of radium-223 in routine clinical practice

Several treatment options are currently available for patients with metastatic castration-resistant prostate cancer in routine clinical practice. However, clear standards of sequential use of registered drugs have not yet been developed. Affecting bone metastases, radium-223 is one of therapeutic options for patients with castration-resistant prostate cancer and bone metastases, which was included in foreign and Russian guidelines for prostate cancer management. This article analyzes the results of treatment with radium-223 in patients with metastatic castration-resistant prostate cancer in foreign non-interventional clinical trials conducted in routine clinical practice. These trials confirmed high efficacy and safety of radium-223 demonstrated earlier in the ALSYMPCA trial. Some protocols ensured better overall survival rates and lower incidence of symptomatic skeletal events and adverse events than those in the registration study.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Onkourologiya ONCOLOGY-

CiteScore

0.40

自引率

0.00%

发文量

审稿时长

10 weeks

期刊介绍： The main objective of the journal "Cancer urology" is publishing up-to-date information about scientific clinical researches, diagnostics, treatment of oncologic urological diseases. The aim of the edition is to inform the experts on oncologic urology about achievements in this area, to build understanding of the necessary integrated interdisciplinary approach in therapy, alongside with urologists, combining efforts of doctors of various specialties (cardiologists, pediatricians, chemotherapeutists et al.), to contribute to raising the effectiveness of oncologic patients’ treatment.